These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 30677005)

  • 41. Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration Based on Single-Arm Trials.
    Tibau A; Molto C; Borrell M; Del Paggio JC; Barnadas A; Booth CM; Amir E
    JAMA Oncol; 2018 Nov; 4(11):1610-1611. PubMed ID: 30267037
    [TBL] [Abstract][Full Text] [Related]  

  • 42. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer?
    Seyednasrollah F; Mahmoudian M; Rautakorpi L; Hirvonen O; Laitinen T; Jyrkkiö S; Elo LL
    Eur Urol; 2017 May; 71(5):838-840. PubMed ID: 28189430
    [No Abstract]   [Full Text] [Related]  

  • 43. Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel.
    Fernández O; Afonso J; Vázquez S; Campos B; Lázaro M; León L; Antón Aparicio LM
    Anticancer Drugs; 2014 Mar; 25(3):237-43. PubMed ID: 24217332
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Drug design strategies for the treatment of prostate cancer.
    Lauer RC; Friend SC; Rietz C; Pasqualini R; Arap W
    Expert Opin Drug Discov; 2015 Jan; 10(1):81-90. PubMed ID: 25366417
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration.
    Tibau A; Ocana A; Anguera G; Seruga B; Templeton AJ; Barnadas A; Amir E
    JAMA Oncol; 2016 Jun; 2(6):744-50. PubMed ID: 26940233
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Radium 223 dichloride for prostate cancer treatment.
    Deshayes E; Roumiguie M; Thibault C; Beuzeboc P; Cachin F; Hennequin C; Huglo D; Rozet F; Kassab-Chahmi D; Rebillard X; Houédé N
    Drug Des Devel Ther; 2017; 11():2643-2651. PubMed ID: 28919714
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist's perspective.
    Shore ND
    Urology; 2015 Apr; 85(4):717-24. PubMed ID: 25681834
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Updated:
    Boni G; Monari F
    Tumori; 2019 Jun; 105(3):271. PubMed ID: 30866748
    [No Abstract]   [Full Text] [Related]  

  • 49. Practical guide to the use of chemotherapy in castration resistant prostate cancer.
    Petrylak DP
    Can J Urol; 2014 Apr; 21(2 Supp 1):77-83. PubMed ID: 24775728
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Management of castration-resistant (advanced) prostate cancer (CRPC): rationale, progress and future directions.
    Chopra S; Rashid P
    Aust Fam Physician; 2015 May; 44(5):302-5. PubMed ID: 26042402
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.
    Bahl A; Masson S; Birtle A; Chowdhury S; de Bono J
    Cancer Treat Rev; 2014 Feb; 40(1):170-7. PubMed ID: 23958310
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary.
    Kluetz PG; Pierce W; Maher VE; Zhang H; Tang S; Song P; Liu Q; Haber MT; Leutzinger EE; Al-Hakim A; Chen W; Palmby T; Alebachew E; Sridhara R; Ibrahim A; Justice R; Pazdur R
    Clin Cancer Res; 2014 Jan; 20(1):9-14. PubMed ID: 24190979
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Apalutamide shows efficacy in prostate cancer.
    Gourd E
    Lancet Oncol; 2018 Mar; 19(3):e149. PubMed ID: 29456088
    [No Abstract]   [Full Text] [Related]  

  • 54. PARP inhibition in castration-resistant prostate cancer.
    Nappi L; Gleave ME
    Future Oncol; 2016 Mar; 12(5):577-80. PubMed ID: 26792387
    [No Abstract]   [Full Text] [Related]  

  • 55. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
    Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The value of new drugs for advanced prostate cancer.
    Howard DH; Quek RGW; Fox KM; Arondekar B; Filson CP
    Cancer; 2021 Sep; 127(18):3457-3465. PubMed ID: 34062620
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dovitinib reduces prostate cancer bone metastases.
    Cancer Discov; 2014 Nov; 4(11):OF3. PubMed ID: 25367965
    [No Abstract]   [Full Text] [Related]  

  • 58. Progress in the mechanism and drug development of castration-resistant prostate cancer.
    Zuo M; Xu X; Li T; Ge R; Li Z
    Future Med Chem; 2016 May; 8(7):765-88. PubMed ID: 27149562
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeted agents: the rules of combination.
    Kwak EL; Clark JW; Chabner B
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5232-7. PubMed ID: 17875749
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The diffusion of docetaxel in patients with metastatic prostate cancer.
    Unger JM; Hershman DL; Martin D; Etzioni RB; Barlow WE; LeBlanc M; Ramsey SR
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25540245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.